Exclusive Summary

• Highly cost-competitive with zero patent barriers, perfectly addressing the massive and essential primary chronic medication needs of hypertensive populations in Low- and Middle-Income Countries (LMICs).
• As a classic Single-Pill Combination (SPC), it significantly simplifies dosing regimens and robustly improves long-term patient compliance within grassroots medical systems.
• The mature manufacturing processes and large-scale capacity of Chinese suppliers can strategically fill the global supply gap caused by the discontinuation of classic legacy antihypertensives, ensuring a stable, high-volume supply chain.
• Positioned as an incredibly cost-effective basic essential generic, it is highly ideal for winning government procurement tenders or aggressively penetrating grassroots distribution channels in emerging markets.